atenolol and disopyramide: what the product label says

The product label for atenolol names disopyramide in its drug-interaction information. The complete selected section is reproduced below so that qualifications stay with the finding.

Which products this evidence covers

Atenolol — TABLET — ORAL

Labeled active ingredients: ATENOLOL. Routes: ORAL. Dosage forms: TABLET.

Supporting label passage

Section: Drug Interactions

Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS ). Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Beta-blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta-blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta-blockers should be delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta-blockers in the acute myocardial infarction setting. While taking beta-blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Read the full product label on DailyMed. Label version 1, dated 2026-10-19.

Limits of this evidence

This passage applies to the labeled product and circumstances it describes. It must not be generalized to other routes or formulations. It does not independently validate CDI’s severity category, establish safety for an individual, or replace the full label. The stored interaction description and classification have not been changed by this article.

How this brief was prepared

Automatic checks matched drug identities, retrieved and preserved the label, and checked the full quoted section with AI assistance on 2026-11-11. The public explanation uses a fixed template; model-written medical advice is not published. Independent clinical review has not been recorded.

Discuss your exact medicines with your pharmacist

Ask your pharmacist or prescriber whether the cited products, routes and circumstances apply to your medicines before changing treatment.

Check your medication list with CDI.